Paraoxonase-1 is associated with corneal endothelial cell alterations in patients with chronic obstructive pulmonary disease

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 8, 2013, Pages 5852-5858

  Soler, Núria ^a   García Heredia, Anabel ^a   Marsillach, Judit ^b   Mackness, Bharti ^a   Mackness, Michael ^a   Joven, Jorge ^a   Romero, Pere ^a   Camps, Jordi ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Cataracts; Corneal endothelial cells; Specular microscopy

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CORTICOSTEROID; GLUCONOLACTONASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CATARACT; CELL DENSITY; CELL STRUCTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORNEA CELL; CORNEA THICKNESS; CROSS-SECTIONAL STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FORCED EXPIRATORY VOLUME; HUMAN; HYDROLYSIS; HYPOXEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PULSE OXIMETER; SPECTROPHOTOMETRY; SPECULAR MICROSCOPY; SPIROMETRY; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

CATARACTS; CORNEAL ENDOTHELIAL CELLS; SPECULAR MICROSCOPY;

ANALYSIS OF VARIANCE; AQUEOUS HUMOR; ARYLDIALKYLPHOSPHATASE; CATARACT EXTRACTION; CROSS-SECTIONAL STUDIES; ENDOTHELIAL CELLS; ENDOTHELIUM, CORNEAL; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84883243058     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-11951     Document Type: Article

References (53)

1. Stanojkovic I, Kotur-Stevuljevic J, Milenkovic B, et al. Pulmonary function, oxidative stress and inflammatory markers in severe COPD exacerbation. Respir Med. 2011;105:S31-S37.
2. Løkke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax. 2006;61:935-939.
3. Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest. 2011;139:165-173.
4. Drost EM, Skwarski KM, Sauleda J, et al. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax. 2005;60:293-300.
5. Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J. 2008;31:1334-1356.
6. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of "overspill" of inflammatory mediators from the lungs? Review of the evidence. Thorax. 2010;65:930-936.
7. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33:1165-1185.
8. Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31:204-212.
9. Vogtel M, Michels A. Role of intermittent hypoxia in the treatment of bronchial asthma and chronic obstructive pulmonary disease. Curr Opin Allergy Clin Immunol. 2010; 10:206-213.
10. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD006829.
11. Miller DP, Watkins SE, Sampson T, Davis KJ. Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database. Int J Chron Obstruct Pulmon Dis. 2011;6:467-476.
12. Truscott RJ. Age-related nuclear cataract-oxidation is the key. Exp Eye Res. 2005;80:709-725.
13. Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci. 2009;46:83-106.
14. Rodríguez-Sanabria F, Rull A, Beltrán-Debón R, et al. Tissue distribution and expression of paraoxonases and chemokines in mouse: the ubiquitous and joint localisation suggest a systemic and coordinated role. J Mol Histol. 2010;41:379-386.
15. Marsillach J, Mackness B, Mackness M, et al. Immunochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic Biol Med. 2008;45:146-157.
16. Deakin SP, Bioletto S, Bochaton-Piallat ML, James RW. HDLassociated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radic Biol Med. 2011;50:102-109.
17. Torres-Ramos YD, Guzman-Grenfell AM, Montoya-Estrada A, et al. RBC membrane damage and decreased band 3 phosphotyrosine phosphatase activity are markers of COPD progresi ón. Front Biosci (Elite Ed). 2010;2:1385-1393.
18. Isik B, Isik RS, Ceylan A, Calik O. Trace elements and oxidative stress in chronic obstructive pulmonary disease. Saudi Med J. 2005;26:1882-1885.
19. Van Schaick W, van Dooren BT, Mulder PG, Völker-Dieben HJ. Validity of endothelial cell analysis methods and recommendations for calibration in Topcon SP-2000P specular microscopy. Cornea. 2005;24:538-544.
20. Cheung SW, Cho P. Endothelial cells analysis with the TOPCON specular microscope SP-2000P and IMAGEnet system. Curr Eye Res. 2000;21:788-798.
21. Reddy ST, Wadleigh DJ, Grijalva V, et al. Human paraoxonase-3 is an HDL associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol. 2001;21:542-547.
22. Gaidukov L, Tawfik D. The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity. J Lipid Res. 2007;48:1637-1646.
23. Marsillach J, Aragonès G, Beltrán R, et al. The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clin Biochem. 2009;42:91-98.
24. Ferré N, Camps J, Prats E, et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem. 2002;48:261-268.
25. Sadowska AM, van Overveld FJ, Górecka D, et al. The interrelationship between markers of inflammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidant. Respir Med. 2005;99:241-249.
26. Wouters EF. Chronic obstructive pulmonary disease. 5: systemic effects of COPD. Thorax. 2002;57:1067-1070.
27. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574-580.
28. Costa LG, Giordano G, Cole TB, Marsillach J, Furlong CE. Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity. Toxicology. 2013;307:115-122.
29. Torres-Ramos YD, Montoya-Estrada A, Guzman-Grenfell AM, et al. Urban PM2.5 induces ROS generation and RBC damage in COPD patients. Front Biosci (Elite Ed). 2011;3:808-817.
30. Furlong CE, Richter RJ, Li WF, et al. The functional consequences of polymorphisms in the human PON1 gene. In: Mackness B, Mackness M, Aviram M, Paragh G, eds. The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism. Dordrecht, Netherlands: Springer; 2008:267-382.
31. Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999;26:892-904.
32. Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci (Lond.). 2000;98:355-363.
33. Inoue M, Suehiro T, Nakamura T, Ikeda Y, Kumon Y, Hashimoto K. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism. 2000;49:1400-1405.
34. Barathi S, Angayarkanni N, Pasupathi A, et al. Homocysteinethiolactone and paraoxonase: novel markers of diabetic retinopathy. Diabetes Care. 2010;33:2031-2037.
35. Baskol G, Karakucuk S, Oner AO, et al. Serum paraoxonase 1 activity and lipid peroxidation levels in patients with age-related macular degeneration. Ophthalmologica. 2006;220:12-16.
36. Ates O, Azizi S, Alp HH, et al. Decreased serum paraoxonase 1 activity and increased serum homocysteine and malondialdehyde levels in age-related macular degeneration. Tohoku J Exp Med. 2009;217:17-22.
37. Hashim Z, Ilyas A, Saleem A, Salim A, Zarina S. Expression and activity of paraoxonase 1 in human cataractous lens tissue. Free Radic Biol Med. 2009;46:1089-1095.
38. Hashim A, Zarina S. Assessment of paraoxonase activity and lipid peroxidation levels in diabetic patients and senile subjects suffering from cataract. Clin Biochem. 2007;40: 705-709.
39. Liton PB, Luna C, Challa P, Epstein DL, Gonzalez P. Genomewide expression profile of human trabecular meshwork cultured cells, nonglaucomatous and primary open angle glaucoma tissue. Mol Vis. 2006;12:774-790.
40. Ghanem AA, Arafa LF, El-Baz A. Oxidative stress markers in patients with primary open-angle glaucoma. Curr Eye Res. 2010;35:295-301.
41. Zheng Y, Liu Y, Ge J, et al. Resveratrol protects human lens epithelial cells against H2O2-induced oxidative stress by increasing catalase, SOD-1, and HO-1 expression. Mol Vis. 2010;16:1467-1474.
42. Cenedella RJ. Lipoproteins and lipids in cow and human aqueous humor. Biochim Biophys Acta. 1984;793:448-454.
43. Bagnis A, Izzotti A, Centofanti M, Saccà SC. Aqueous humor oxidative stress proteomic levels in primary open angle glaucoma. Exp Eye Res. 2012;103:55-62.
44. Ishizaki M, Zhu G, Haseba T, Shafer SS, Kao WW. Expression of collagen I, smooth muscle alpha-actin, and vimentin during the healing of alkali-burned and lacerated corneas. Invest Ophthalmol Vis Sci. 1993;34:3320-3328.
45. Jakobiec FA, Bhat P. Retrocorneal membranes: a comparative immunohistochemical analysis of keratocytic, endothelial, and epithelial origins. Am J Ophthalmol. 2010;150:230-242.
46. Agusti A, Soriano JB. COPD as a systemic disease. COPD. 2008; 5:133-138.
47. Agustí AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:347-360.
48. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J. 2006;28:219-242.
49. Sagoo P, Chan G, Larkin DF, George AJ. Inflammatory cytokines induce apoptosis of corneal endothelium through nitric oxide. Invest Ophthalmol Vis Sci. 2004;45:3964-3973.
50. Balaiya S, Edwards J, Tillis T, Khetpal V, Chalam KV. Tumor necrosis factor-alpha (TNF-α) levels in aqueous humor of primary open angle glaucoma. Clin Ophthalmol. 2011;5: 553-556.
51. Shivanna M, Srinivas SP. Microtubule stabilization opposes the (TNF-alpha)-induced loss in the barrier integrity of corneal endothelium. Exp Eye Res. 2009;89:950-959.
52. Schmedt T, Silva MM, Ziaei A, Jurkunas U. Molecular bases of corneal endothelial dystrophies. Exp Eye Res. 2012;95:24-34.
53. Pearson M. Is the primary mechanism underlying COPD: inflammation or ischemia? COPD. 2013;10:536-541.